

Product data sheet



MedKoo Cat#: 524338 Name: Pavinetant CAS: 941690-55-7 Chemical Formula: C ₂₆ H ₂₅ N ₃ O ₃ S Exact Mass: 459.1617 Molecular Weight: 459.564	
Product supplied as: Powder	
Purity (by HPLC): ≥ 98%	
Shipping conditions: Ambient temperature	
Storage conditions: Powder: -20°C 3 years; 4°C 2 years. In solvent: -80°C 3 months; -20°C 2 weeks.	

1. Product description:

Pavinetant, also known as MLE-4901, AZD-4901, AZ-12472520, and AZD-2624, is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which is under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS). It was also under investigation for the treatment of schizophrenia, but development was discontinued for this indication due to lack of effectiveness. As of 2017, the drug is in phase II clinical trials for hot flashes and PCOS.

2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under “QC And Documents” section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	50.0	108.80

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.18 mL	10.88 mL	21.76 mL
5 mM	0.44 mL	2.18 mL	4.35 mL
10 mM	0.22 mL	1.09 mL	2.18 mL
50 mM	0.04 mL	0.22 mL	0.44 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of “Calculator”

6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

Li Y, Zhou D, Ferguson SS, Dorff P, Simpson TR, Grimm SW. In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies. *Xenobiotica*. 2010 Nov;40(11):721-9. doi: 10.3109/00498254.2010.512670. PMID: 20937004.

In vivo study

TBD

7. Bioactivity

Biological target:

Pavinetant (MLE-4901) is a neurokinin-3 receptor (NK3R) antagonist.

In vitro activity

Product data sheet



The metabolic drug-drug interaction potential of AZD2624 was evaluated in in vitro studies. AZD2624 exhibited an inhibitory effect on microsomal CYP3A4/5 activities with apparent IC(50) values of 7.1 and 19.8 μ M for midazolam and testosterone assays, respectively.

Reference: Xenobiotica. 2010 Nov;40(11):721-9. <https://pubmed.ncbi.nlm.nih.gov/20937004/>

In vivo activity

TBD

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.